Cargando…

Latest combination therapies in psoriasis: Narrative review of the literature

Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Diotallevi, Federico, Paolinelli, Matteo, Radi, Giulia, Offidani, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786636/
https://www.ncbi.nlm.nih.gov/pubmed/35959523
http://dx.doi.org/10.1111/dth.15759
_version_ 1784858333573808128
author Diotallevi, Federico
Paolinelli, Matteo
Radi, Giulia
Offidani, Annamaria
author_facet Diotallevi, Federico
Paolinelli, Matteo
Radi, Giulia
Offidani, Annamaria
author_sort Diotallevi, Federico
collection PubMed
description Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have long been used in combination with traditional topical and systemic therapies to induce a complete remission of the disease that could not be achieved with innovative drug alone. Even with the advent of new biological therapies with more precise molecular targets, the challenge of using combination therapies remained. Psoriatic patients often have major comorbidities, such as arthritis, inflammatory bowel disease, uveitis or have other concomitant conditions such as chronic spontaneous urticaria and atopic dermatitis, which may require different biologic treatments than those indicated in psoriasis. The objective of this article is, through a comprehensive revision of the literature, to analyze in which cases the use of the combination of the latest therapies for psoriasis may be useful.
format Online
Article
Text
id pubmed-9786636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-97866362022-12-27 Latest combination therapies in psoriasis: Narrative review of the literature Diotallevi, Federico Paolinelli, Matteo Radi, Giulia Offidani, Annamaria Dermatol Ther Review Articles Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have long been used in combination with traditional topical and systemic therapies to induce a complete remission of the disease that could not be achieved with innovative drug alone. Even with the advent of new biological therapies with more precise molecular targets, the challenge of using combination therapies remained. Psoriatic patients often have major comorbidities, such as arthritis, inflammatory bowel disease, uveitis or have other concomitant conditions such as chronic spontaneous urticaria and atopic dermatitis, which may require different biologic treatments than those indicated in psoriasis. The objective of this article is, through a comprehensive revision of the literature, to analyze in which cases the use of the combination of the latest therapies for psoriasis may be useful. John Wiley & Sons, Inc. 2022-08-26 2022-10 /pmc/articles/PMC9786636/ /pubmed/35959523 http://dx.doi.org/10.1111/dth.15759 Text en © 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
Diotallevi, Federico
Paolinelli, Matteo
Radi, Giulia
Offidani, Annamaria
Latest combination therapies in psoriasis: Narrative review of the literature
title Latest combination therapies in psoriasis: Narrative review of the literature
title_full Latest combination therapies in psoriasis: Narrative review of the literature
title_fullStr Latest combination therapies in psoriasis: Narrative review of the literature
title_full_unstemmed Latest combination therapies in psoriasis: Narrative review of the literature
title_short Latest combination therapies in psoriasis: Narrative review of the literature
title_sort latest combination therapies in psoriasis: narrative review of the literature
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786636/
https://www.ncbi.nlm.nih.gov/pubmed/35959523
http://dx.doi.org/10.1111/dth.15759
work_keys_str_mv AT diotallevifederico latestcombinationtherapiesinpsoriasisnarrativereviewoftheliterature
AT paolinellimatteo latestcombinationtherapiesinpsoriasisnarrativereviewoftheliterature
AT radigiulia latestcombinationtherapiesinpsoriasisnarrativereviewoftheliterature
AT offidaniannamaria latestcombinationtherapiesinpsoriasisnarrativereviewoftheliterature